# Papers related to study of eye diseases and eye disorders


## 2022
[Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials](https://www.sciencedirect.com/science/article/pii/S0140673622000101)

## 2021

[Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results](https://bjo.bmj.com/content/105/2/253?fbclid=IwAR0zmLJRrgysLAoaI-J62aTxvot2-DhW_6zB5Tf9a4errdoYHMrawA-kQ8Y)

[Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes](https://www.sciencedirect.com/science/article/pii/S0002939421000453)

## 2019

[Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes](https://www.sciencedirect.com/science/article/pii/S000293941930056X)

## 2017

[Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: Trex-dme 1 year outcomes](https://www.sciencedirect.com/science/article/pii/S0161642016313537)

## 2015
[Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results](https://www.sciencedirect.com/science/article/pii/S0161642015007861)
